SpikoGen®
Keypoints
SpikoGen is a more traditional COVID-19 vaccine comprising SARS-CoV-2 spike protein extracellular domain formulated with Advax-CpG adjuvant
SpikoGen differs from the Novavax vaccine in major ways including its use of the soluble secreted spike protein ECD rather than nanoparticle formulation and the use of a different adjuvant
SpikoGen demonstrates robust protection against homologous and heterologous SARS-CoV-2 strains in hamster, ferret and non-human primate challenge models
SpikoGen induces broadly cross-neutralizing antibodies, but still protects even after these antibody levels wane
In a pivotal Phase 3 clinical trial, SpikoGen reduced the risk of severe infection by 77.5% and was not associated with myocarditis, thrombosis or any other adverse safety signals
SpikoGen received an Emergency Use Authorization in the Middle East on 6 October 2021, making it the first recombinant spike protein vaccine to achieve this milestone
Eight million doses of SpikoGen vaccine have been safely delivered to date
Protein-based vaccines have a long history of reliability and safety
Unlocking resources
Collaboration & Potential
We work together with innovative biotech developers to your drug production destination means the world to us, and our dedicated team of experts will support and guide you from the earliest stage of development through commercialization and beyond.
